Hector Perez, MD
Family Medicine · Fort Wayne, INNPI 1952385866
Payments from drug & device makers
Across 400 payments — averaging $39.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Lilly USA, LLC$2K
- Novo Nordisk$2K
- AbbVie$2K
- Boehringer Ingelheim$1K
- AstraZeneca$1K
- GSK$962
- plus $7K from 30 others
What the payments were for
- Food & beverage$15,566100%
- Education$780%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Lilly USA, LLC | 49 | $1,829 |
| Novo Nordisk | 67 | $1,788 |
| AbbVie(2 entities) | 50 | $1,552 |
| Boehringer Ingelheim | 28 | $1,318 |
| AstraZeneca | 30 | $1,078 |
| GSK | 26 | $962 |
| Axsome Therapeutics, Inc. | 7 | $818 |
| Amgen | 7 | $638 |
| Bayer | 5 | $574 |
| Sanofi-aventis U.S. LLC | 15 | $573 |
| Pfizer | 13 | $567 |
| Johnson & Johnson | 16 | $396 |
| Abbott | 3 | $364 |
| Phathom Pharmaceuticals, Inc. | 3 | $350 |
| Merck | 19 | $237 |
| Amarin Pharma, Inc. | 17 | $231 |
| Biohaven Pharmaceutical Holding Company Ltd. | 2 | $214 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 7 | $203 |
| Vanda Pharmaceuticals Inc. | 5 | $172 |
| Lupin Inc. | 3 | $172 |
| Medtronic | 1 | $152 |
| Eisai Inc. | 3 | $150 |
| Stryker | 1 | $143 |
| Idorsia Pharmaceuticals US Inc | 2 | $142 |
| Paratek Pharmaceuticals, Inc. | 1 | $125 |
| Nestle Healthcare Nutrition Inc. | 1 | $124 |
| Dexcom, Inc. | 1 | $121 |
| Dynavax Technologies Corporation | 1 | $110 |
| Axonics, Inc. | 1 | $104 |
| Ironwood Pharmaceuticals, Inc | 1 | $97 |
| Takeda Pharmaceuticals U.S.A., Inc. | 6 | $97 |
| Kowa Pharmaceuticals America, Inc. | 5 | $94 |
| Otsuka America Pharmaceutical, Inc. | 1 | $91 |
| Exact Sciences | 1 | $28 |
| Assertio Therapeutics, Inc. | 1 | $17 |
| Novartis | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$15,644 in reported general payments places this provider in the 95th percentile of 2,709 family medicine providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 56 | $122,167 |
| JardianceEmpagliflozin | 48 | $75,678 |
| MounjaroTirzepatide | 28 | $47,340 |
| FarxigaDapagliflozin Propanediol | 46 | $43,446 |
| JanuviaSitagliptin Phosphate | 28 | $36,697 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 38 | $35,534 |
| TradjentaLinagliptin | 18 | $26,977 |
| EliquisApixaban | 28 | $24,354 |
| LinzessLinaclotide | 17 | $23,170 |
| Toujeo SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $21,124 |
| TrulicityDulaglutide | 14 | $17,897 |
| XareltoRivaroxaban | 11 | $16,012 |
| JanumetSitagliptin Phos/Metformin Hcl | 15 | $9,248 |
| Tresiba Flextouch U-100Insulin Degludec | 13 | $7,504 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 60 | $6,850 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,788 | $122,16756 claims |
| Boehringer IngelheimJardiance, Tradjenta | $1,318 | $102,65566 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,829 | $65,23842 claims |
| MerckJanuvia, Janumet | $237 | $45,94543 claims |
| AstraZenecaFarxiga | $1,078 | $43,44646 claims |
| GSKTrelegy Ellipta | $962 | $35,53438 claims |
| AbbVieLinzess, Synthroid | $1,552 | $24,55637 claims |
| PfizerEliquis | $567 | $24,35428 claims |
| Johnson & JohnsonXarelto | $396 | $16,01211 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,709 family medicine providers in Indiana.
Other family medicine in Fort Wayne
- Thomas KintanarFort Wayne$185K
- Brianna SerbusFort Wayne$174K
- Brian AdamsFort Wayne$173K
- Charles CoatsFort Wayne$38K
- Beulah PenumudiFort Wayne$38K
- Blair BrengleIndianapolis$10.6M
- Laura HelmanMishawaka$4M
- J Christopher SartoreEvansville$3.9M
- Hubert ReyesEvansville$3.2M
- David SchultzEvansville$3M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.